Our analysis integrating network pharmacology and RNA-seq data suggests that CE inhibits cholesterol synthesis in SCLC cells by downregulating key enzymes in the cholesterol biosynthesis pathway, including HMGCR, IDI1, FDFT1, and SQLE. This evidence concerns the gene FDFT1 and small cell lung carcinoma.